The Motivations for Using Tears to Confirm Parkinson Disease Diagnosis: Mark Lew, MD
The director of the Division of Movement Disorders at the USC Keck School of Medicine commented on the potential of reflex tears as a critical biomarker of Parkinson disease. [WATCH TIME: 6 minutes]
WATCH TIME: 6 minutes
"It made sense to try and look at the proteinaceous constituents of tear fluid. Additionally, tear fluid is easy to collect. It’s noninvasive, inexpensive. It’s not like when you do a lumbar puncture, which is a much more involved ordeal, there’s risk of contamination with blood, saliva is dirty, issues with blood and collection. It’s much safer and less expensive to do."
In an analysis presented at the
Values measured by enzyme-linked immunosorbent assay, or ELISA, showed a 5.4-fold increase in oligomeric α-synuclein in those with early-stage PD (4.28 [±0.75] ng/mg tear protein; P <.001), a 4.0-fold increase for intermediate PD (3.23 [±0.54] ng/mg tear protein; P <.001) and a 3.1-fold increase for late-stage PD (2.44 [±0.40] ng/mg tear protein; P <.001). Led by Mark Lew, MD, the study expanded on previous findings which first identified these elevated protein levels in both basal tears and reflex tears.
In an interview with NeurologyLive®, Lew, director of the Division of Movement Disorders at the USC Keck School of Medicine, echoed the thoughts of other movement disorder experts, noting the dire need for biomarkers of PD that can formalize diagnosis and show medication response. He also provided background on the previous that led to this new analysis, how tears are collected, and the advantages they bring over traditional biomarkers.
REFERENCE
1. Lew M, Janga S, Ju Y, et al. Biomarkers for Parkinson disease with reflex tears stratified by disease duration. Presented at: 2022 AAN Annual Meeting; April 2-7, Seattle, Washington. Abstract 3750
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025